Navigation Links
Mount Sinai’s Simulation Lab Proves Effective in Training Anesthesiologists Reentering Practice
Date:5/31/2013

(PRWEB) May 31, 2013

Results of a study on 10 years of experience retraining anesthesiologists in a simulation program at the Icahn School of Medicine at Mount Sinai reveal that 70 percent of participants returned to active practice within one year of completing the program. The study’s findings are available online and will appear in the July print edition of the journal Anesthesiology.

The study is an analysis of the simulation program used to retrain and assess anesthesiologists’ skills over decade, between 2002 and 2012. A pioneer in simulation, the Icahn School of Medicine at Mount Sinai’s Simulation Lab was one of the first of its kind, launched in 1994 under Adam I. Levine, MD, the study’s senior author. Dr. Levine is also Professor of Anesthesiology, Otolaryngology, Structural and Chemical Biology at Mount Sinai, and Director of the American Society of Anesthesiologists Endorsed Program, the Mount Sinai Human Emulation, Education, and Evaluation Lab for Patient Safety and Professional Study (HELPS).

“We had 20 anesthesiologists referred to our program during the study period,” said Dr. Levine. Fourteen anesthesiologists returned to active practice within one year of completing the program.

“Reentry programs for anesthesiologists are urgently needed and are of great interest to the American Society of Anesthesiologists and The American Board of Anesthesiology,” said Dr. Levine. “Strengths of our program are that it permits evaluation of core competencies, yet is adaptable enough to permit a focused evaluation and reeducation for the individual physician.”

Mount Sinai’s Department of Anesthesiology’s simulation lab uses full-scale patient mannequins with palpable pulses, breath and heart sounds that can physiologically respond to a variety of intravenous and inhaled anesthetic drugs through the interaction of sophisticated sensors and robust cardiovascular and pulmonary computer-driven modeling. The simulation lab is used to teach the management of complex perioperative medical events and emergencies, including difficult airway management, recognition and management of ischemia and cardiac arrest, and other rare and critical pulmonary and cardiovascular events.

“We see this as one day being an adjunct, or even replacement, to the current oral and written anesthesiology board structure,” said the study’s lead author, Samuel DeMaria, Jr., MD, Assistant Professor of Anesthesiology at Mount Sinai. What differentiates the program from oral and written assessments is it allows participants to show what they would do during a crisis, not just say what they would do, and all without putting actual patients at risk.

Other study coauthors from the Icahn School of Medicine at Mount Sinai include Stefan T. Samuelson, MD, Fellow, Simulation Center, Andrew D. Schwartz, MD, Instructor of Anesthesiology, and Alan J. Sim, MD, Assistant Professor of Anesthesiology.

####

Read the full story at http://www.prweb.com/releases/2013/5/prweb10788975.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Intermountain Vein Center Announces Groundbreaking Guidelines in Treatment of Acute Ischemic Stroke
2. Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports
3. Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles
4. Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration
5. Air Conditioning Birmingham AL 'Best of the Best' Awarded to Aire Serv of Over The Mountain for Excellence by Follow Media Consulting, Inc.
6. Icahn School of Medicine at Mount Sinai and Bene Pharmachem Gmbh to Collaborate on Clinical Studies for Mucopolysaccaridoses
7. Paramount Oral Surgery Announces New Oral Exam Procedures Designed to Reduce Wisdom Teeth Pain
8. Tiger Schulmann’s Mixed Martial Arts Opens New Location In Mount Kisco, New York
9. Mount Sinai Researchers Identify Gene Mutations in Congenital Heart Disease
10. Icahn School of Medicine at Mount Sinai Honors Innovators in Scientific Research and Health Care Philanthropy at 2013 Commencement Ceremony
11. The Mount Sinai Medical Center Adopts HIPAA-Compliant Mobile Care App Across the Enterprise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Tucson, AZ (PRWEB) , ... February 10, 2016 , ... ... prompted the Aging Life Care Association™ (ALCA) to conduct a survey that takes a ... aging experts released today illustrates the prevalence and causes of TBI among the aging ...
(Date:2/10/2016)... ... 10, 2016 , ... United Benefit Advisors (UBA), the nation’s ... to its growing list of Partner Firms. S.S. Nesbitt is headquartered in ... Huntsville and in between. , Harnessing the experience and insights of the agency’s ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... AxoGen, Inc. ... will report results for the fourth quarter and full year ended December 31, 2015 ... a conference call and webcast for the investment community following the release at 4:30 ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association for ... speaker Jan Fox will serve as keynote speaker at the organization’s 2016 Spring ... tools to more effectively communicate with their own organizational staff and leadership. ...
(Date:2/10/2016)... AZ (PRWEB) , ... February 10, 2016 , ... For ... in new book , Pioneering book "Better with Age: The Ultimate Guide to Brain ... neuroplasticity can improve memory. The book’s publication date is March 16, 2016. ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... NEW YORK , Feb. 10, 2016 ... clinical-stage biopharmaceutical company, announced today that it has filed ... Myeloid Leukemia and other cancers. --> ... of treating cancer by administration of Ceplene (histamine dihydrochloride) ... also provides methods of predicting the efficacy of Ceplene ...
(Date:2/10/2016)... , Feb. 10, 2016  Oxis International Inc. ... drug, OXS-1550, was described as a "clinical trial triumph" ... drug went into complete cancer remission. ... of Minnesota Masonic Cancer Center. --> ... of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology: